JNJ-98768111 for Advanced Prostate Cancer
Prostate cancer develops in the prostate gland and can sometimes spread to other areas of the body. When cancer spreads, doctors call it advanced prostate cancer. At this stage, standard treatments may become less effective, meaning new options are urgently needed. This clinical trial is testing an experimental medicine named JNJ-98768111. It is a Phase 1 trial, which means this is the very first time the drug is being given to humans. The main goal of this early research is not yet to prove whether it shrinks tumours, but to ensure it is safe to use, understand how the body processes it, and work out the safest dose. The trial is open to men aged 18 and older who have advanced prostate cancer. Joining the study is completely voluntary, and participants receive regular health checks, scans, and blood tests to monitor their wellbeing.
At a glance
What is this study about?
Prostate cancer is one of the most common cancers found in men. In many cases, it grows slowly and can be managed well. However, in some men, the cancer spreads beyond the prostate to the bones or other organs. When this happens, it is known as advanced prostate cancer. While there are standard therapies available to slow the disease, these treatments can eventually stop working, so researchers continue to look for new ways to target cancer cells.
This trial is looking at an experimental drug called JNJ-98768111. It is classified as a 'Phase 1' or 'first-in-human' study. Before a new drug can be approved as a regular treatment, it must pass through several stages of testing. Phase 1 is the earliest stage. Its main focus is to discover how human bodies handle the medicine, what side effects might happen, and what dose is safe and manageable.
Because this is the first time JNJ-98768111 is being given to people, doctors start with very small doses and slowly increase them in new groups of patients if it is safe to do so. This step-by-step approach helps researchers gather vital safety data. Finding the right dose is crucial so that future, larger studies can test whether the drug can effectively slow or stop cancer growth.
Key takeaways
- The trial tests a new drug called JNJ-98768111 for advanced prostate cancer.
- This is a Phase 1 study, meaning the drug is being given to humans for the first time.
- The primary focus is testing safety, identifying side effects, and finding the best dose.
- Participation requires regular hospital visits, blood tests, and scans.
- Taking part is completely voluntary, and you can withdraw at any time.
Who may be eligible?
This trial is specifically for men aged 18 or older who have been diagnosed with advanced prostate cancer. Usually, trials like this are designed for people whose cancer has continued to grow or spread despite receiving standard treatments, such as hormone therapies or chemotherapy.
To be considered, participants must generally be well enough to carry out everyday activities and attend regular hospital visits. The trial team will also check that key organs, such as your heart, liver, and kidneys, are working well enough to process the study medicine safely.
You might not be able to join if you have certain other serious medical conditions, recent infections, or if you have had specific cancer treatments too close to the start of the study. A doctor on the trial team will review your full medical history to confirm whether the study is a safe and suitable option for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am a man aged 18 or older.
- I have been diagnosed with advanced or spreading prostate cancer.
- Standard treatments are no longer working well for my cancer.
- I am well enough to travel to hospital appointments regularly.
- I am willing to undergo frequent health checks, blood tests, and scans.
What does participation involve?
If you take part, your care will begin with a screening period where doctors run health checks, blood tests, and scans to confirm you are eligible. Once accepted, you will receive the study medicine, JNJ-98768111, which may be given as a tablet or through a drip into a vein. You will need to visit the hospital frequently, especially during the first few weeks, so the medical team can monitor your vital signs, take blood samples, and check how your body responds. You will also have regular scans to track your cancer. The total length of the trial varies: you may remain on the study for as long as the treatment remains safe for you and shows potential benefit, followed by check-ups to monitor your recovery.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is a Phase 1 clinical trial?
A Phase 1 trial is the earliest stage of human testing. It focuses on finding out if a new drug is safe, what side effects it causes, and what dose works best.
Will taking this drug cure my prostate cancer?
It is unlikely to cure advanced cancer. The main aim of this early study is to check safety and dosing rather than cure the disease.
Do I have to pay to take part in the study?
No, clinical trials in the UK do not charge participants for the trial medicine or tests. Travel expenses may also be reimbursed.
Can I leave the trial if I change my mind?
Yes. Taking part is entirely voluntary, and you can leave at any point without giving a reason and without harming your ongoing medical care.
What happens if I experience severe side effects?
The medical team will treat your symptoms immediately. If necessary, they will lower your dose, pause the medication, or stop it altogether.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.